Research Article
Prognostic Value of Plasma Pentraxin-3 Levels in Patients with Stable Coronary Artery Disease after Drug-Eluting Stent Implantation
Table 1
Clinical characteristics of patients with and without MACEs.
| | | All patients ( = 596) | Patients without MACEs ( = 514) | Patients with MACEs ( = 82) | value |
| | Age (years) | 65.9 (8.1) | 65.3 ± 8.1 | 69.7 ± 7.3 | 0.000 | | Male, (%) | 467 (78.4) | 402 (78.2) | 65 (79.3) | 0.886 | | CCSA class > II, (%) | 184 (30.9) | 149 (29.0) | 35 (42.7) | 0.015 | | LVEF < 50%, (%) | 178 (29.8) | 145 (28.2) | 33 (40.2) | 0.037 | | Diabetes mellitus, (%) | 92 (15.4) | 73 (14.6) | 19 (20.7) | 0.047 | | Hypertension, (%) | 319 (53.5) | 272 (52.9) | 47 (57.3) | 0.477 | | Hyperlipidemia, (%) | 192 (32.2) | 164 (31.9) | 28 (34.1) | 0.704 | | Current smoking, (%) | 182 (30.5) | 153 (29.8) | 29 (35.4) | 0.368 | | cTnI (ng/mL) | 0.23 ± 0.16 | 0.20 ± 0.12 | 0.37 ± 0.24 | 0.000 | | HsCRP (ng/mL) | 3.27 ± 1.19 | 3.14 ± 1.14 | 4.09 ± 1.16 | 0.000 | | In-hospital therapy | | | | | | Aspirin, (%) | 596 (100) | 514 (100) | 82 (100) | | | Clopidogrel, (%) | 596 (100) | 514 (100) | 82 (100) | | | -Blockers, (%) | 465 (78.0) | 404 (78.6) | 61 (74.4) | 0.391 | | ACE-I or ARB, (%) | 532 (89.3) | 463 (90.1) | 69 (84.1) | 0.123 | | Statins, (%) | 596 (100) | 514 (100) | 82 (100) | | | Types of DES | | | | | | Sirolimus, (%) | 390 (65.4) | 334 (65.0) | 56 (68.3) | 0.618 | | Zotarolimus, (%) | 130 (21.8) | 113 (22.0) | 17 (20.7) | 0.886 | | Paclitaxel, (%) | 63 (10.6) | 53 (10.3) | 10 (12.2) | 0.565 | | Others, (%) | 13 (2.2) | 10 (1.9) | 3 (3.7) | 0.403 | | Multiple stents, (%) | 238 (39.9) | 190 (37.0) | 48 (58.5) | 0.0004 |
|
|
CCSA: Canadian Cardiovascular Society Angina; LVEF: left ventricular ejection fraction; PTX3: pentraxin-3; cTnI: cardiac troponin I; HsCRP: high-sensitivity C-reactive protein; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin-receptor blocker.
|
